Allarity Therapeutics Files 8-K

Ticker: ALLR · Form: 8-K · Filed: Mar 25, 2025 · CIK: 1860657

Sentiment: neutral

Topics: sec-filing, 8-k, regulatory-update

Related Tickers: ALLR

TL;DR

Allarity Therapeutics filed an 8-K on 3/24/25. No major news yet.

AI Summary

Allarity Therapeutics, Inc. filed an 8-K on March 24, 2025, reporting other events and financial statements. The company, incorporated in Delaware, has its principal executive offices in Boston, MA. This filing does not appear to contain specific transactional details or financial figures beyond the reporting date.

Why It Matters

This 8-K filing indicates a routine update from Allarity Therapeutics, Inc. to the SEC, which may contain important disclosures about the company's operations or financial status.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not disclose any immediate material changes or negative news.

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by Allarity Therapeutics, Inc. in this 8-K filing?

The provided text of the 8-K filing does not detail the specific 'Other Events' being reported, only that this item is included.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on March 24, 2025.

What is the principal executive office address for Allarity Therapeutics, Inc.?

The principal executive office address for Allarity Therapeutics, Inc. is 24 School Street, 2nd Floor, Boston, MA 02108.

What is the standard industrial classification for Allarity Therapeutics, Inc.?

The standard industrial classification for Allarity Therapeutics, Inc. is Pharmaceutical Preparations [2834].

Does this 8-K filing disclose any financial statements or exhibits?

Yes, the filing indicates 'Financial Statements and Exhibits' as an item information, but the specific content of these is not detailed in the provided text.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 25, 2025 regarding Allarity Therapeutics, Inc. (ALLR).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing